Novartis AG Stock Price, News & Analysis (NYSE:NVS)

$85.08 0.60 (0.71 %)
(As of 11/24/2017 06:29 AM ET)
Previous Close$84.48
Today's Range$84.90 - $85.35
52-Week Range$66.93 - $86.90
Volume733,965 shs
Average Volume1.72 million shs
Market Capitalization$199.85 billion
P/E Ratio17.78
Dividend Yield2.73%
Beta0.72

About Novartis AG (NYSE:NVS)

Novartis AG logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.32%
Current Ratio1.08%
Quick Ratio0.81%

Price-To-Earnings

Trailing P/E Ratio17.78
Forward P/E Ratio17.91
P/E Growth2.69

Sales & Book Value

Annual Sales$48.52 billion
Price / Sales4.15
Cash Flow$4.80 per share
Price / Cash17.73
Book Value$30.59 per share
Price / Book2.78

Profitability

Trailing EPS$2.81
Net Income$6.71 billion
Net Margins13.73%
Return on Equity15.77%
Return on Assets8.46%

Miscellaneous

Employees123,000
Outstanding Shares2,365,590,000

Frequently Asked Questions for Novartis AG (NYSE:NVS)

What is Novartis AG's stock symbol?

Novartis AG trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis AG pay dividends? What is the dividend yield for Novartis AG?

Novartis AG announced an annual dividend on Friday, January 27th. Shareholders of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date is Wednesday, March 1st. View Novartis AG's Dividend History.

How will Novartis AG's stock buyback program work?

Novartis AG announced that its Board of Directors has initiated a share buyback program on Saturday, April 8th 2017, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board of directors believes its stock is undervalued.

How were Novartis AG's earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, October, 24th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.25 by $0.04. The firm had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The business's quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.23 EPS. View Novartis AG's Earnings History.

When will Novartis AG make its next earnings announcement?

Novartis AG is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Novartis AG.

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

13 analysts have issued 12-month target prices for Novartis AG's shares. Their predictions range from $74.37 to $91.00. On average, they expect Novartis AG's stock price to reach $84.41 in the next twelve months. View Analyst Ratings for Novartis AG.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee (Age 57)
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee (Age 51)
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee (Age 48)
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee (Age 60)
  • Steven Baert, Head of Human Resources, Member of the Executive Committee (Age 42)
  • Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee

Who owns Novartis AG stock?

Novartis AG's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Parnassus Investments CA (0.40%), Fisher Asset Management LLC (0.25%), Manning & Napier Advisors LLC (0.19%), Mawer Investment Management Ltd. (0.11%), Earnest Partners LLC (0.08%) and Janus Henderson Group PLC (0.08%). Company insiders that own Novartis AG stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis AG.

Who sold Novartis AG stock? Who is selling Novartis AG stock?

Novartis AG's stock was sold by a variety of institutional investors in the last quarter, including Sei Investments Co., Manning & Napier Advisors LLC, Sectoral Asset Management Inc, Dimensional Fund Advisors LP, Assetmark Inc., Private Asset Management Inc., Tdam USA Inc. and First Republic Investment Management Inc.. View Insider Buying and Selling for Novartis AG.

Who bought Novartis AG stock? Who is buying Novartis AG stock?

Novartis AG's stock was acquired by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Boston Partners, Amundi Pioneer Asset Management Inc., Russell Investments Group Ltd., Crossmark Global Holdings Inc., Fisher Asset Management LLC, Principal Financial Group Inc. and Seatown Holdings Pte. Ltd.. Company insiders that have bought Novartis AG stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis AG.

How do I buy Novartis AG stock?

Shares of Novartis AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis AG's stock price today?

One share of Novartis AG stock can currently be purchased for approximately $85.08.

How big of a company is Novartis AG?

Novartis AG has a market capitalization of $199.85 billion and generates $48.52 billion in revenue each year. The company earns $6.71 billion in net income (profit) each year or $2.81 on an earnings per share basis. Novartis AG employs 123,000 workers across the globe.

How can I contact Novartis AG?

Novartis AG's mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis AG (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  337 (Vote Underperform)
Total Votes:  616
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Novartis AG (NYSE:NVS)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.142.142.142.10
Ratings Breakdown: 3 Sell Rating(s)
12 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
13 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
13 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
12 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $86.12$86.12$83.56$83.38
Price Target Upside: 5.36% upside5.83% upside0.97% upside2.87% upside

Consensus Price Target History for Novartis AG (NYSE:NVS)

Price Target History for Novartis AG (NYSE:NVS)

Analysts' Ratings History for Novartis AG (NYSE:NVS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
10/25/2017Barclays PLCDowngradeEqual Weight -> UnderweightN/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$89.00 -> $91.00N/AView Rating Details
8/9/2017Cowen IncSet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
3/22/2017Goldman Sachs Group IncReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche Bank AGReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
7/12/2016Bank of America CorporationReiterated RatingHoldN/AView Rating Details
5/24/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for Novartis AG (NYSE:NVS)

Earnings by Quarter for Novartis AG (NYSE:NVS)

Earnings History by Quarter for Novartis AG (NYSE NVS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018        
10/24/20179/30/2017$1.25$1.29$12.21 billion$12.41 billionViewN/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novartis AG (NYSE:NVS)
2017 EPS Consensus Estimate: $4.72
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20172$1.15$1.22$1.19
Q3 20172$1.24$1.25$1.25
Q4 20171$1.17$1.17$1.17
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Novartis AG (NYSE:NVS)

Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.70%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:81.85% (Trailing 12 Months of Earnings)
48.42% (Based on This Year's Estimates)
45.19% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis AG (NYSE:NVS)

Dividend History by Quarter for Novartis AG (NYSE NVS)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Novartis AG (NYSE NVS)

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.74%
Insider Trades by Quarter for Novartis AG (NYSE:NVS)
Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Insider Trades by Quarter for Novartis AG (NYSE NVS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Novartis AG (NYSE NVS)

Source:
DateHeadline
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents DataPharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data
finance.yahoo.com - November 24 at 9:19 AM
Novartis AG (NVS) a Buy on Solid Earnings VisibilityNovartis AG (NVS) a Buy on Solid Earnings Visibility
investorplace.com - November 24 at 8:51 AM
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion ... - NasdaqNovartis (NVS) Receives EC Nod for Tasigna Label Expansion ... - Nasdaq
www.nasdaq.com - November 23 at 7:03 AM
Contrasting Novartis AG (NVS) & Its CompetitorsContrasting Novartis AG (NVS) & Its Competitors
www.americanbankingnews.com - November 20 at 1:30 AM
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy - Investorplace.comImproving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy - Investorplace.com
investorplace.com - November 19 at 2:59 AM
Novartis AG (NVS) versus Cambrex Corporation (CBM) Head to Head SurveyNovartis AG (NVS) versus Cambrex Corporation (CBM) Head to Head Survey
www.americanbankingnews.com - November 18 at 11:14 AM
How Novartis’s Tasigna Is Looking NowHow Novartis’s Tasigna Is Looking Now
finance.yahoo.com - November 18 at 9:23 AM
Behind 4 Key Novartis Money Makers (and Losers) in 3Q17Behind 4 Key Novartis Money Makers (and Losers) in 3Q17
finance.yahoo.com - November 18 at 9:23 AM
CMS Administrator Seema Verma To Outline Her Plan At 2017 Forbes Healthcare SummitCMS Administrator Seema Verma To Outline Her Plan At 2017 Forbes Healthcare Summit
finance.yahoo.com - November 18 at 9:23 AM
How 2 Key Novartis Oncology Drugs Performed in 3Q17How 2 Key Novartis Oncology Drugs Performed in 3Q17
finance.yahoo.com - November 18 at 9:23 AM
How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17?How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17?
finance.yahoo.com - November 18 at 9:23 AM
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to BuyImproving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy
investorplace.com - November 17 at 12:21 PM
Novartis (NVS) Arms Biosimilars Study Results Encourage - NasdaqNovartis (NVS) Arm's Biosimilars Study Results Encourage - Nasdaq
www.nasdaq.com - November 15 at 6:56 AM
Novartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III TrialNovartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III Trial
www.finanznachrichten.de - November 14 at 6:17 AM
Novartis launches heart drug counter-offensiveNovartis launches heart drug counter-offensive
finance.yahoo.com - November 14 at 6:17 AM
Novartis posts eye drug data amid play for Eyleas turfNovartis posts eye drug data amid play for Eylea's turf
finance.yahoo.com - November 12 at 11:07 AM
Better Buy: Exelixis, Inc. vs. Novartis AGBetter Buy: Exelixis, Inc. vs. Novartis AG
finance.yahoo.com - November 12 at 11:07 AM
Solid Quant Score Metrics Drive Upgrade of Novartis AG (NVS) to BuySolid Quant Score Metrics Drive Upgrade of Novartis AG (NVS) to Buy
investorplace.com - November 10 at 9:27 AM
Comparing Novartis AG (NVS) & Its RivalsComparing Novartis AG (NVS) & Its Rivals
www.americanbankingnews.com - November 9 at 10:27 AM
Novartis takes fight to Pfizers Ibrance with new Kisqali dataNovartis takes fight to Pfizer's Ibrance with new Kisqali data
finance.yahoo.com - November 9 at 7:51 AM
Novartis: MONALEESA-7 Trial Meets Primary Endpoint Of Progression-free Survival - NasdaqNovartis: MONALEESA-7 Trial Meets Primary Endpoint Of Progression-free Survival - Nasdaq
www.nasdaq.com - November 8 at 2:46 AM
Novartis: Cosentyx Reduced Signs Of Psoriatic Arthritis In Future 5 StudyNovartis: Cosentyx Reduced Signs Of Psoriatic Arthritis In Future 5 Study
www.rttnews.com - November 7 at 4:30 PM
ETFs with exposure to Novartis AG : November 6, 2017ETFs with exposure to Novartis AG : November 6, 2017
finance.yahoo.com - November 7 at 4:30 PM
Here's Why Advanced Accelerator Application SA Rose 20% in OctoberHere's Why Advanced Accelerator Application SA Rose 20% in October
finance.yahoo.com - November 7 at 4:29 PM
Novartis AG (NVS) Receives Consensus Rating of "Hold" from BrokeragesNovartis AG (NVS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 6 at 5:48 PM
Novartis, Amgen Report Expanded Collaboration With Banner Alzheimers InstituteNovartis, Amgen Report Expanded Collaboration With Banner Alzheimer's Institute
www.finanznachrichten.de - November 4 at 4:01 PM
Earnings Review and Free Research Report: Novartis’ Sales Grew 2%; EPS Jumped 10%Earnings Review and Free Research Report: Novartis’ Sales Grew 2%; EPS Jumped 10%
finance.yahoo.com - November 4 at 4:01 PM
Anemic Earnings Growth Hurts Novartis AG (NVS) Rating - Investorplace.comAnemic Earnings Growth Hurts Novartis AG (NVS) Rating - Investorplace.com
investorplace.com - November 4 at 8:14 AM
Novartis Reportedly Taps Centerview to Evaluate Options for Dermatology BusinessNovartis Reportedly Taps Centerview to Evaluate Options for Dermatology Business
finance.yahoo.com - November 4 at 8:14 AM
Anemic Earnings Growth Hurts Novartis AG (NVS) RatingAnemic Earnings Growth Hurts Novartis AG (NVS) Rating
investorplace.com - November 3 at 9:24 AM
Critical Comparison: Novartis AG (NVS) and Its CompetitorsCritical Comparison: Novartis AG (NVS) and Its Competitors
www.americanbankingnews.com - November 2 at 8:42 AM
FY2017 EPS Estimates for Novartis AG Lifted by Analyst (NVS)FY2017 EPS Estimates for Novartis AG Lifted by Analyst (NVS)
www.americanbankingnews.com - November 2 at 8:17 AM
Novartis Is Said to Weigh Sale of Dermatology Generics BusinessNovartis Is Said to Weigh Sale of Dermatology Generics Business
finance.yahoo.com - November 1 at 7:04 AM
Novartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm - Wall Street JournalNovartis to Pay $3.9 Billion for Radio-Pharmaceuticals Firm - Wall Street Journal
www.wsj.com - October 31 at 7:14 AM
Novartis asks FDA to expand Kymriahs use against blood cancerNovartis asks FDA to expand Kymriah's use against blood cancer
finance.yahoo.com - October 31 at 7:14 AM
Novartis asks FDA to expand Kymriahs use against blood cancerNovartis asks FDA to expand Kymriah's use against blood cancer
finance.yahoo.com - October 31 at 7:14 AM
Novartis AG (NVS) Earnings Momentum Hurts Rating - Investorplace.comNovartis AG (NVS) Earnings Momentum Hurts Rating - Investorplace.com
investorplace.com - October 28 at 3:26 PM
Novartis AG (NVS) Earnings Momentum Hurts RatingNovartis AG (NVS) Earnings Momentum Hurts Rating
investorplace.com - October 27 at 9:25 AM
Novartis: EMA Accepts Sandoz Biosimilar Pegfilgrastim For Regulatory ReviewNovartis: EMA Accepts Sandoz' Biosimilar Pegfilgrastim For Regulatory Review
www.rttnews.com - October 27 at 8:50 AM
Glaxo (GSK) Q3 Earnings Surpass Estimates, Revenues In LineGlaxo (GSK) Q3 Earnings Surpass Estimates, Revenues In Line
finance.yahoo.com - October 27 at 8:50 AM
Novartis AG :NVS-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017Novartis AG :NVS-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017
finance.yahoo.com - October 27 at 8:50 AM
ETFs with exposure to Novartis AG : October 26, 2017ETFs with exposure to Novartis AG : October 26, 2017
finance.yahoo.com - October 27 at 8:49 AM
FY2017 EPS Estimates for Novartis AG Increased by Analyst (NVS)FY2017 EPS Estimates for Novartis AG Increased by Analyst (NVS)
www.americanbankingnews.com - October 26 at 9:16 AM
Novartis AG (NVS) Expected to Post FY2021 Earnings of $6.32 Per ShareNovartis AG (NVS) Expected to Post FY2021 Earnings of $6.32 Per Share
www.americanbankingnews.com - October 25 at 7:36 PM
Comparing Novartis AG (NVS) and Akorn (AKRX)Comparing Novartis AG (NVS) and Akorn (AKRX)
www.americanbankingnews.com - October 25 at 7:12 PM
Novartis AG (NVS) Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNovartis AG (NVS) Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - October 25 at 8:25 AM
[$$] Novartis May Still Spin Off Alcon, but Not Before 2019[$$] Novartis May Still Spin Off Alcon, but Not Before 2019
finance.yahoo.com - October 25 at 8:24 AM
Todays Research Reports on Stocks to Watch: Novartis AG and Sarepta TherapeuticsToday's Research Reports on Stocks to Watch: Novartis AG and Sarepta Therapeutics
finance.yahoo.com - October 25 at 8:24 AM
Leerink Swann Comments on Novartis AGs FY2020 Earnings (NVS)Leerink Swann Comments on Novartis AG's FY2020 Earnings (NVS)
www.americanbankingnews.com - October 24 at 3:50 PM
Novartis AG (NVS) Issues Quarterly  Earnings Results, Beats Expectations By $0.04 EPSNovartis AG (NVS) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - October 24 at 9:18 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Novartis AG (NYSE NVS) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.